Results 161 to 170 of about 48,363 (248)

Effects of lipid-lowering drugs on epilepsy and its subtypes: A drug-target Mendelian randomization study. [PDF]

Medicine (Baltimore)
Wang Y, Huang S.
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 1 (PCSK1) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]

Rev Cardiovasc Med
Theofilis P, Vlachakis PK, Karakasis P, Iliakis P, Pamporis K, Oikonomou E, Dimitriadis K, Tsioufis K, Tousoulis D.   +8 more
europepmc   +1 more source

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]

Rev Assoc Med Bras (1992)
Costa ALDS, Santos JED, Salgado Junior W, Bertoncini-Silva C, Bizari L, Moura GSPL, Liberatore Junior RDR, Zorzo RA, Suen VMM.   +8 more
europepmc   +1 more source

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study. [PDF]

J Int Med Res
Wang Y, Liu X, Huang S.
europepmc   +1 more source

Proprotein convertase subtilisin/ kexin type 9 levels and arterial function

Atherosclerosis, 2018
Koutagiar, I., Vlachopoulos, C., Terentes-Printzios, D., Skoumas, J., Skliros, N., Rigatou, A., Ioakeimidis, N., Pantou, S., Georgakopoulos, C., Miliou, A., Tousoulis, D.   +10 more
openaire   +2 more sources

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. [PDF]

Front Med (Lausanne)
Zhou Q, Liu X, Tang Y, Pan C, Bi X.
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease. [PDF]

Atheroscler Plus
Ugovšek S, Rehberger Likozar A, Levstek T, Trebušak Podkrajšek K, Zupan J, Marka F, Trimmel T, Brekalo M, Speidl W, Hohensinner P, Haider P, Šebeštjen M.   +11 more
europepmc   +1 more source

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source